mScarlet/LUC Reporter Cell Line - BXPC-3

BXPC-3 is a human pancreatic ductal adenocarcinoma (PDAC) cell line established from a primary pancreatic tumor and is widely used as a representative model for pancreatic cancer research. The cell line exhibits epithelial morphology and retains many molecular features characteristic of pancreatic adenocarcinoma, making it valuable for investigating tumor growth, invasion, metastasis, and therapeutic response. Unlike several other pancreatic cancer cell lines, BXPC-3 is KRAS wild-type, which provides a unique experimental platform for studying alternative oncogenic pathways and evaluating targeted therapeutic strategies. The mScarlet/LUC Reporter Cell Line - BXPC-3 is generated through stable integration of the red fluorescent protein mScarlet and firefly luciferase (LUC) reporter genes into parental BXPC-3 cells. This dual-reporter system enables high-sensitivity fluorescence imaging and quantitative bioluminescence monitoring while preserving the biological characteristics and tumorigenic properties of the original cell line.

The BXPC-3-mScarlet/LUC reporter cell line is widely utilized in pancreatic cancer research for real-time assessment of tumor progression and therapeutic efficacy. Luciferase expression enables non-invasive longitudinal monitoring of tumor burden, metastatic spread, and treatment response in xenograft and orthotopic pancreatic cancer models through bioluminescence imaging. Concurrently, mScarlet expression provides bright and stable red fluorescence, facilitating visualization of cellular morphology, proliferation, migration, invasion, and tissue distribution at high resolution. This model is particularly useful for evaluating chemotherapeutic agents, targeted therapies, immunotherapeutic approaches, and combination treatment regimens for pancreatic adenocarcinoma. In addition, the dual-reporter platform supports mechanistic studies of tumor–microenvironment interactions, epithelial–mesenchymal transition, cancer stem cell-associated phenotypes, and signaling pathways involved in pancreatic tumor progression. With stable reporter expression and robust imaging performance, the BXPC-3-mScarlet/LUC cell line provides a reliable and reproducible tool for preclinical drug discovery, efficacy evaluation, and translational research in pancreatic cancer.